Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer.

G.E.C. Osborne(University Hospitals Sussex NHS Foundation Trust), Alistair Ring(National Health Service), Duncan C. Gilbert(Royal Sussex County Hospital), M. Herreros Villanueva, Fiona McKinna, Angus Robinson(Royal Sussex County Hospital), Ashok Nikapota(University Hospitals Sussex NHS Foundation Trust)
Journal of Clinical Oncology
February 1, 2014
10.1200/jco.2014.32.4_suppl.184
Cited by 0

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Mechanisms of tamoxifen resistance
|Endocrine Related Cancer|2004|652
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
|JAMA Oncology|2019|425